PMID- 32164494
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20200803
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 132
IP  - 4
DP  - 2020 May
TI  - Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal 
      disease: results from a cardiovascular and renal outcomes trial.
PG  - 314-319
LID - 10.1080/00325481.2020.1742524 [doi]
AB  - Review of: Rosenstock J, Perkovic V, Johansen, OE, et al. Effect of linagliptin 
      vs placebo on major cardiovascular events in adults with type 2 diabetes and high 
      cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 
      2019;321:69-79. McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects 
      on heart failure and related outcomes in individuals with type 2 diabetes 
      mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 
      2019;139:351-361. These two papers describe the findings from the CARMELINA trial 
      (Cardiovascular and Renal Microvascular Outcome Study with Linagliptin): the 
      first paper reported results for the primary cardiovascular composite outcome 
      (cardiovascular [CV] death, nonfatal myocardial infarction [MI], or nonfatal 
      stroke; 3-point major adverse cardiovascular event [3P-MACE]) and the key 
      secondary renal composite outcome (renal death, end-stage kidney disease, or 
      sustained >/=40% decrease in eGFR from baseline); the second paper reported 
      secondary analyses of heart failure (HF) and related outcomes. The CARMELINA 
      trial was a randomized, placebo-controlled, multicenter non-inferiority trial of 
      adults with type 2 diabetes mellitus (T2DM) and elevated CV and renal risk. After 
      a median 2.2-year follow-up of 6979 participants, patients allocated to 
      linagliptin demonstrated no increase in the risk of 3P-MACE versus placebo: 
      hazard ratio (HR) 1.02 [95% confidence interval (CI) 0.89-1.17]; P < 0.001 for 
      non-inferiority. There was also no increase in the risk of hospitalization for HF 
      for linagliptin versus placebo (HR 0.90 [0.74-1.08]). There was no increased risk 
      of progression to end-stage kidney disease or death due to kidney disease (HR 
      0.87 [0.69-1.10]). Additionally, progression of albuminuria occurred less 
      frequently in patients who received linagliptin versus placebo (HR 0.86 
      [0.78-0.95]). Overall, no new safety findings were identified for linagliptin, 
      and no increased risk of hypoglycemia was observed for linagliptin versus 
      placebo. Together, these findings from the CARMELINA trial reaffirm treatment 
      guidelines for choosing additional therapies for patients with T2DM at elevated 
      CV and/or renal risk, and provide new information on the role of linagliptin in 
      the management of T2DM.
FAU - Guthrie, Robert
AU  - Guthrie R
AD  - The Department of Emergency Medicine, The Ohio State University , Dublin, OH, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200320
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 3X29ZEJ4R2 (Linagliptin)
SB  - IM
MH  - Aged
MH  - Albuminuria/epidemiology/physiopathology
MH  - Cardiovascular Diseases/*epidemiology/mortality/physiopathology
MH  - Diabetes Mellitus, Type 2/*drug therapy/*epidemiology
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Kidney Diseases/*epidemiology/mortality/physiopathology
MH  - Linagliptin/*therapeutic use
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - cardiovascular events
OT  - heart failure
OT  - linagliptin
OT  - renal events
EDAT- 2020/03/14 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/03/14 06:00
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/03/14 06:00 [entrez]
AID - 10.1080/00325481.2020.1742524 [doi]
PST - ppublish
SO  - Postgrad Med. 2020 May;132(4):314-319. doi: 10.1080/00325481.2020.1742524. Epub 
      2020 Mar 20.